 Tarsus Pharmaceuticals Inc NASDAQ: TARS has reported topline data from Phase 2b3 Saturn-1 trial evaluating TP-03 lotilaner ophthalmic solution, 0.25 in patients with Demodex blepharitis. 81 of patients achieved a significant, clinically meaningful collarette cure compared to 23 of those on the vehicle primary endpoint. 